Deaths of Despair: Prescriptive Authority of Psychologists and Suicides

Authors:

Agnitra Roy Choudhury^a Alicia Plemmons^b

August 2021 Working Paper

The Center for Growth and Opportunity at Utah State University is a university-based academic research center that explores the scientific foundations of the interaction between individuals, business, and government.

This working paper represents scientific research that is intended for submission to an academic journal. The views expressed in this paper are those of the author(s) and do not necessarily reflect the views of the Center for Growth and Opportunity at Utah State University or the views of Utah State University.

^b Assistant Professor of Economics, Department of Economics & Finance, Southern Illinois University Edwardsville. Email: aplemmo@siue.edu; Office Phone: (618) 650-3472



^a Visiting Assistant Professor, Department of Economics, Auburn University at Montgomery. Email: achoudhu@aum.edu; Office Phone: (334) 244-3505

Abstract

Suicide rates in the United States have been increasing for the past several years. Limited access to mental healthcare has many adverse effects, especially for marginalized communities. Between 2002 and 2017, five states (NM, LA, IL, IA, and ID) passed legislation allowing psychologists to prescribe psychotropic medication when deemed necessary for patient care, popularly referred to as the RxP movement. Using Vital Mortality Statistics, a restricted data set provided through the National Center for Health Statistics, we determine the effect of state-level expansions of prescriptive authority of psychologists on suicide rates. Using a difference-in-difference estimation strategy, we find that the rate of suicide decreased for males, White populations, individuals who are married or single, and for people between the ages of 35 and 55. Our results suggest that the effect of relaxing the regulations occurs at least 2 to 3 years after the policy change, possibly due to education, training, and experience requirements for psychologists before they can exercise prescriptive privileges.

Keywords: Occupational Regulation, Psychologists, Scope of Practice, RxP Movement, Prescriptive Authority, Suicide

JEL Codes: L51, I12, I18

Disclaimer: Any analysis, interpretations, or conclusions reached are those of the authors and not of NCHS, which is responsible only for the initial data.

1. Introduction

Suicide is one of the leading causes of death in the United States (CDC, 2020). It is the second leading cause of death among individuals between the ages of 15 to 34. Over the past two decades, mortality resulting from suicide increased in nearly all 50 states and the District of Columbia. Over 44,000 lives were lost to suicide in 2016 alone (CDC, 2018). While there are many factors responsible for a person taking their own life, several studies have found strong associations between mental health issues and risk of suicide, with depression being ranked as the most prevalent catalyst (Arsenault-Lapierre et al., 2004; Bachmann, 2018; Brådvik, 2018; Chesney et al., 2014; Too et al., 2019). Improved access to mental healthcare might mitigate the "deaths of despair" and save some lives. Access problems are further highlighted by looking at the higher rates of suicide in rural areas underserved by healthcare providers (Bureau of Health Workforce, 2016).

In the United States, there can often be weeks or months between the time a psychologist identifies that a patient needs pharmacological intervention and when that patient is able to be seen, assessed, and given treatment by a separate psychiatrist. Those weeks or months can be a matter of life or death for individuals with suicidal intentions and expanding psychologist prescriptive authority reduces this time delay. Within this study, we investigate the effect of this prescriptive authority expansion on the most severe potential mental and behavioral health outcome, suicide.

We use restricted mortality data provided through the National Center for Health Statistics to analyze the impact on suicide rates of allowing psychologists prescriptive authority. Prescriptive authority means that, after meeting training, education, and experience requirements, psychologists can prescribe mental and behavioral health medication that they deem beneficial for the individual. Prescriptive authority is one of two types of scope-of-practice regulations within the medical field, the other being practice authority. In economics, several studies have linked scope-of-practice regulations to limits in access to healthcare services. Most studies focus on changes in practice authority, identifying changes in autonomy over job responsibilities. Within our study, psychologist autonomy in patient care did not change; instead the legal change was with the expansion of the right to prescribe medication. This is a unique addition to the literature since it explores one of the few policy vehicles that target prescriptive rather than practice authority.

Access problems can occur because of higher prices of healthcare services due to restrictive scope-of-practice laws (Kleiner et al., 2016; Kleiner & Park, 2010; Timmons & Norris, 2018). Most papers studying scope-of-practice laws focus on dental services (Kleiner & Park, 2010; Kleiner et al., 2016; Langelier et all, 2016), primary care vs. nurse practitioners (Dueker et al., 2005; Stange, 2014; Xue et al., 2016; Traczysnki & Udalova, 2018), and physician assistants (Timmons, 2017). Our paper instead focuses on mental healthcare and suicide through psychologist scope of practice in terms of prescriptive authority, a market that has not been studied thoroughly in the literature.

The Prescription Privileges movement (hereafter RxP movement) is an ongoing policy debate that seeks to expand scope-of-practice privileges for psychologists to prescribe controlled substances. Mental healthcare services usually take two fundamental and often complementary forms: psychotherapy (such as talk therapy) and psychotropic medication. Allowing psychologists to prescribe psychotropic medication may increase access to treatment, particularly for disadvantaged or minority populations. Currently, there are five states where prescriptive authority exists: New Mexico (since 2002), Louisiana (since 2004), Illinois (since 2014), Iowa (since 2016), and Idaho (since 2017) (Alexander & Schnell, 2019). States that allow prescriptive privilege to psychologists require them to complete additional training, education, and experience requirements in psychopharmacology. These requirements create a substantial lagged effect between when a policy is passed and when psychologists are first able to prescribe psychotropic medications to patients.

Proponents of the RxP movement argue that allowing psychologists to prescribe controlled substances will improve access to mental healthcare services. Opponents of the policy state that quality of care will

be poor, and patients may be prescribed inappropriate amounts of medication for their diagnoses. Existing literature in occupational licensing and scope of practice suggest mixed results on quality metrics for reductions in regulatory barriers, with some studies recording improvements due to better access to care. Our paper contributes to this research by analyzing how mortality due to suicides is affected by mental healthcare access by allowing psychologists to prescribe controlled substances. We use a difference-in-difference estimation strategy to determine whether prescription privileges for psychologists mitigate suicide deaths in states allowing prescriptive authority relative to others. We find that, in the long term, states with prescriptive authority have a reduction in suicides for men, women, Black, White, middle-aged, single, and divorced subpopulations.

The rest of the paper is organized as follows. Section 2 describes how our study fits with the existing literature and highlights our main contributions. Section 3 provides the methodology used in the paper while Section 4 describes the data sets used for our analysis. We present the results from our findings in Section 5 and provider the conclusion in Section 6.

2. Literature Review

Scope-of-practice regulations refer to state-level laws that dictate what types of specific procedures can or cannot be performed by healthcare providers. There are significant variations in scope-of-practice regulations across states, and across healthcare professions such as nurse practitioners, physician assistants, and pharmacists (McMichael, 2017; Stein et al., 2017). For instance, nurse practitioners in Alabama must collaborate under a supervising physician before they can order diagnostic tests. However, nurse practitioners in New Mexico do not need to collaborate with physicians, can order tests, and have prescriptive authority to prescribe medication without physician oversight (AANP, 2016).

Proponents state that scope-of-practice regulations promote better quality healthcare services and protection of physicians, who have invested more years to receive their degree. They also state that relaxing scope-of-practice laws might lead to overutilization of diagnostic testing (such as CT scan or MRI) and lead to higher healthcare costs and adverse health outcomes (Hughes et al., 2015). Regarding mental healthcare, this would translate to overprescribing psychotropic medications, which has a higher potential of being abused (Kaminer et al., 2010; Mamat et al., 2015). Regardless of the severity of scope-of-practice restrictions within a state, these restrictions are designed and implemented by state-based agencies such as the board of medicine, board of pharmacy, and the board of nursing (Phillips et al., 2014). These regulatory boards often include politicians, active members of the profession, and persons who have a vested interested in healthcare training schools (Slivinski, 2020).

However, opponents state that these regulations act as strong barriers to the provision of healthcare services, particularly for disadvantaged and rural residents (Federal Trade Commission, 2014). They also argue that restrictive scope-of-practice regulations cause higher healthcare costs by limiting the supply of healthcare services, which results in longer wait times and poorer long-term health outcomes (Kandrack et al., 2019). Most of the research regarding changes in scope-of-practice laws have focused on the responsibilities of nurse practitioners, pharmacists, dental hygienists, dental assistants, and physician assistants. The literature has found evidence suggesting improved access, increased utilization of healthcare services (Timmons & Norris, 2018; Chen et al., 2020; Swan et al., 2015), and lower prices of healthcare services for customers after scope of practice is expanded to other providers (Kleiner et al., 2016; Kleiner & Park, 2010; Timmons & Norris, 2018).

Access can be especially difficult for mental and behavioral health services because there may be disparities in the willingness of insurance companies to cover this type of care due to parity laws. Lang (2013) finds that mental health parity laws can make it easier for people to access mental healthcare by structuring prices in a way that is more affordable within insurance coverage. Scope-of-practice regulations can also exacerbate the provider shortage crisis prevalent in healthcare today—for mental health services alone, there is a shortage of over 6,000 providers (HRSA, 2021).

Other studies have analyzed the availability of healthcare providers for catering to mental health patients on suicide rates. Multiple studies have found that areas with higher availability of healthcare providers, such as psychiatrists, physicians, and counselors, are associated with lower suicide rates. Tondo et al. (2006) find that higher density of psychiatrists and nonpsychiatrist physicians are associated with lower suicide rates. A different study using data from CDC finds that states with higher proportions of psychiatrists, psychologists, and social workers have lower suicide rates (Thomson Healthcare, 2007). Both studies rely on bivariate analysis, making it difficult to establish a strong causal association because there might be factors that affect both mental health outcomes and availability of providers.

Another variable used by researchers to capture access to mental healthcare services is distance to the nearest provider. McCarthy et al. (2012) study the distance to the nearest Veterans Affairs (VA) mental health provider as a factor affecting risk of suicides for active-duty military veterans. Controlling for so-ciodemographic factors and mental health diagnosis, the authors do not find any evidence suggesting that distance to the nearest VA is a strong predictor of suicide within this population. They only find a significant result for distances greater than 800 miles. However, they do not capture how distance affects lack of visits to a mental health provider in the VA.

Researchers have also found a strong link between federal mental health aid received by states and lower suicide rates. Tondo et al. (2006) find that states receiving more federal mental health aid have lower suicide rates. Their paper finds that federal mental health aid provided to states is a stronger predictor of overall state suicide rates than density of mental healthcare providers or proportion of uninsured individuals. There is also the issue of individuals with suicidal tendencies seeking therapy and treatment, and how successful these treatment methods are. Most mental health treatment is long term, requiring regular meetings and medication for months, years, or continuously. Niederkrotenthaler et al. (2014) use data on individuals that died by suicide between 2005 and 2010 to study the utilization of mental health services prior to death. They find that 38.5% suicide decedents had received mental health care within the previous two months before their death.

There are fewer studies analyzing the impact of scope-of-practice regulations on mental and behavioral healthcare access. In the study most similar to our own, Alexander and Schnell (2019) find that expanding independent scope of practice for nurse practitioners to prescribe controlled substances improves access to mental healthcare and reduces mental health related mortality, including suicides. This is the only study to the best of our knowledge that looks at how expansion of scope of practice affects mental healthcare outcomes. Furthermore, they find that the impact is greater on areas that are underserved, such as rural or minority communities. Our paper differs from theirs in that we focus on expansion of prescription authority specifically for psychologists instead of nurse practitioners, and we then determine how this expansion affects suicide-related mortality. We also make a detailed analysis of how expansion of prescriptive authority affects different groups of people by performing a subsample analysis. Other papers have also found that expanded scope of practice for nurse practitioners might help alleviate disparities in access to mental healthcare services (Bishop et al., 2014; Hartley et al., 2004; Traczynski & Udalova, 2018).

3. Data

To understand the ramifications of prescriptive authority on mental health outcomes, we focus on suicide rates within treated and untreated states before and after prescriptive authority for psychologists was implemented. Though deaths resulting from suicide can have many underlying factors, it is firmly associated as a mental and behavioral health outcome on which prescriptive medication has substantial mitigating effects (Gibbons et al., 2005; Olfson et al., 2003). We use mortality data (multiple cause of death) from

the National Vital Statistics System of the National Center for Health Statistics for years 1999–2018 to analyze changes in deaths due to suicide.¹ This data set contains information on all deaths occurring in the United States and contains categorical information on the cause(s) of death. This information is obtained from death certificates provided through vital statistics offices in all 50 states and the District of Columbia.

We restrict our analysis to include only deaths due to suicide for individuals over the age of 15. We aggregate the data set at the state, month, and year levels to include the number of deaths due to suicide in each month and year for a select state. Observations are aggregated to the state level within months to comply with the disclosure rules outlined in our data usage agreement. We do not report on some age categories above 64 or for some minority populations for lack of robust sample size to comply with the legal requirement. We then include information on the sex of individuals who died by suicide in each state at a given time. We add similar information regarding resident status, education level (high school, some college, bachelors, graduate), marital status (divorced, widowed, single, married), age group (multiple 10-year age intervals), and unemployment rate in the given state during a given month. Therefore, we have both observations of the aggregate number of deaths by suicide in a certain state at a certain time, as well as the different characteristics of people who died by suicide in a certain state at a certain time.

Figure 1 illustrates the average suicide rates per 100,000 individuals for New Mexico and Louisiana relative to the other states. Three things stand out when looking at this graph. First, we see that without controlling for any other factors that might affect suicide rates, New Mexico has a higher overall suicide rate compared to the other states, while Louisiana is more comparable to the national average. Second, the figure shows that the trends for the two reforming states are similar to the nonreforming states (which we include in our control group). Third, we observe that suicide rates have been increasing across all states between 1999 and 2018. We further graph the coefficients of the state-level suicide trend for New Mexico and Louisiana in Figure 2 and notice that our pre-policy change years are not significantly different from the national average trend in the pre-policy period.

Tables 1 and 2 provides the summary statistics of some key variables that illustrate a snapshot of the mortality data, in the most recent sample year, 2018, and before any state changed their policies, 2003. Given the restrictions on data access, there are limitations in the data descriptions that we can report. We list the summary statistics of suicide rates for the nation, and then for the RxP states versus the nontreatment states, for years 2003 and 2018, the year before any policy changes and the last year in our sample, respectively. We see from the table that suicide rates increased from 2003 to 2018 for all groups. Suicide rates are also higher in the treatment states compared to the nontreatment states. This prompts the question of whether the policy implementation was endogenous or not, which we will discuss using a trend analysis. We also see that females only comprise a little over 20% of suicide deaths, which is consistent with the literature. Finally, according to our data, most of the suicides are of White individuals, which is also consistent with previous studies.

4. Methodology

We use a difference-in-difference estimation to investigate the impact of allowing psychologists to have prescriptive authority on access to mental healthcare and quality of care, as measured by suicide, the worst potential outcome. Our main specification is given below:

$$y_{smt} = \beta_0 + \beta_1 Treat_{st} + X_{smt}'C + \alpha_s + \rho_t + \gamma_m + \mu_s^* t + \varepsilon_{smt}$$
(1)

 y_{smt} represents our outcome variables: natural log of suicide rates in a given month *m* in a state *s* in year *t*. We use suicide rates to detect how expanding prescription authority to psychologists affects quality of

¹ We had access to the public data from 1996–2004 from the NBER website. However, NBER discontinued posting geographic identifiers from 2005. We had to apply to NCHS to receive the restricted version of the data set from 2005–2018. Data are aggregated to the state level to comply with restricted data reporting requirements.

care. *Treat*_{st} is an indicator variable that equals 1 for states with prescriptive authority for psychologists, after the policy was implemented. *Treat*_{st} is 0 for all states that do not allow psychologists to prescribe controlled substances. Though five states have changed their scope-of-practice laws for psychologists, the only states that have had enough time since the policy change for the new training, education, and experience requirements to be implemented are New Mexico (since 2002) and Louisiana (since 2004). Psychologists must complete certain training, education, and experience requirements before they are allowed to prescribe controlled substances. For instance, psychologists in New Mexico undergo 450 hours of didactic instruction and 400 hours of supervised practicum before they can prescribe (16 NM § 22.24). In Louisiana, psychologists, 2014). Though the two states have differences in the way they describe their program, the legislation for prescriptive authority is very similar in terms of subject matter, timeline, practicum experience, collaboration requirements, and continuing education requirements. Since the policy was passed in different years for New Mexico and Louisiana, *Treat*_{st} is 1 for New Mexico in 2003, 0 for Louisiana in 2003, 1 for both New Mexico and Louisiana in 2005 and later.

Our coefficient of interest is β_1 , which captures the impact of prescriptive authority. α_s and ρ_t represent state and time fixed effects, respectively. The control states contain all other 48 states. Since we are using staggered implementation periods, Louisiana is a control for New Mexico for 2 years. We assume that the changes in New Mexico policy are plausibly exogenous to Louisiana's pre-reform suicide rate since the training and requirements for a psychologist to obtain prescriptive authority after the policy change in NM would take longer than the amount of time for LA to reform. We do not remove Illinois, Iowa, and Idaho from the control group since they have not had enough time since the policy change to fully implement changes.

Finally, to address for the differential timing of policy change between our treated states, we adopt the Goodman-Bacon (2018) decomposition to disentangle the impact of early adopters (New Mexico) from late adopters (Louisiana). Since both states implemented the law close to one another, we do not expect to see a vast change in the estimates. However, we might see an impact on the weights suggesting whether our estimates are driven mainly by New Mexico or Louisiana.

If expansion of scope of practice does not reduce the quality of mental healthcare, we would expect suicide rates to decline or remain unchanged. Studies within the occupational licensing literature have found mixed effects on quality of care metrics after scope-of-practice regulations were expanded for nurse practitioners. However, if access to mental healthcare improves, we would expect to see a significant decline in the rates of suicide. If the quality of healthcare diminishes, then we might observe an increase in mortality due to suicide. Therefore, the empirical result is theoretically ambiguous.

We further perform a series of subsample analysis to see whether the expansion of prescribing authority to psychologists had an impact on certain populations more than others. We expect larger impacts on minority groups due to greater access problems present in these communities. We also expect that the policy would have a bigger impact on people between the ages of 35 and 55. To test this, we conduct subsample analyses by the sex, marital status, age, and racial categories using the variables provided in the data set. Finally, all standard errors are clustered at the state level to adjust for unobservable confounders that are correlated to the treatment at the state level.

To account for potential confounding factors within states, we empirically go one step further and repeat our analysis with the addition of bootstrapped standard errors, with a rep of 100 and seed of 1. Bootstrapping is a computational method in which we empirically mimic the process of random sampling by treating our observed sample as if it were the population (Giné & Zinn, 1990). We then take samples of the pseudo-population, with replacements, and calculate our estimate of interest. This does not change the coefficient estimate itself but instead reevaluates the standard errors within the updated framework. We check for parallel trends using Angrist and Pischke's (2009) approach. We interact a linear time trend separately with each reforming state to account for the different timing of the policy change. The formal specification of this parallel assumption test is as follows:

$$y_{smt} = \beta_0 + \beta_1 Treat_s + \beta_2 Trend_t + \alpha (Treat_s^* Trend_t) + \gamma_s + \theta_m + \delta_t + X_{smt}'C + \varepsilon_{st} \forall t \le t_0$$
(2)

The parallel assumption test is conducted separately for New Mexico and Louisiana and is applied to the pre-reforming period. For New Mexico, t_0 is equal to 2002, representing the policy reform year, while for Louisiana, t_0 is 2004. The main coefficient of interest is α , which captures the difference in trend between the reforming states and all the other states. When we conduct the specification for New Mexico, the control group includes all other states minus Louisiana. When we run the specification for Louisiana, we drop New Mexico from our analysis. We are interested in both the statistical significance and magnitude of α . If α is small in magnitude and statistically insignificant, we can argue that the parallel trend assumption is plausibly satisfied. X represents a vector of additional controls that are state and time specific, such as proportion of women who died of suicide, residential status, racial controls, education controls, marital status, and age, including macroeconomic variables such as unemployment rate. Finally, we also add a state-specific linear time trend μ_e^*t to capture the change in suicide rates over time within each state.

Though we inspect for pretreatment parallel trends using this methodology, it should also be understood that the parallel trends "test" is not a definitive test of common trends since the true counterfactual in which the states never changed their policy is unobserved. Regardless, inspection of pretreatment trends provides some comfort in the potential validity of parallel trends. We present the results of the parallel assumption test in Tables 3 through 6. Table 3 represents the trend analysis for New Mexico and Louisiana for the full sample, as well as both male and female subsamples. Tables 4, 5, and 6 repeat the analysis for marital status, race, and age, respectively. The coefficient of interest is both small in magnitude and statistically insignificant for most outcome variables. In the few cases where we find a statistically significant. The trend analysis also suggests that the pre-policy trend in suicide rates for Louisiana is statistically closer to the control group in the pre-policy period than New Mexico. However, the magnitudes of α for New Mexico are very small, when statistically significant.

5. Results

We present the regression results for the effect of prescriptive authority on logged overall suicide rates in Table 7. We find that overall suicide rates in our treatment states saw a reduction in the post-policy period of 5 to 7 percentage points, relative to states without prescriptive authority for psychologists. The most restrictive specifications contain controls such as state fixed effects, time fixed effects, and the proportion of suicides within that state for each residency status, education level, marital status, age group, race, and gender. The model also controls for state-level unemployment rates since lack of employment opportunities has been identified as correlated with suicide. These reductions are significant with standard errors clustered at the state level and with bootstrapped standard errors. The analysis is further conducted on a series of subsamples of mortality data by sex, marital status, age group, and race. Since the evidence suggests that access to mental healthcare services is underprovided for certain groups, we expect to see larger magnitudes of estimated changes in suicides for some groups relative to others.

Table 8 shows that suicides decreased for males and increased for females in New Mexico and Louisiana following the passage of prescriptive policy for psychologists. This is interesting since male mortality due to suicide is higher, and females are a smaller sample of the suicide mortality population. The first two columns do not include additional controls. Our estimates suggest that the suicide rates for men in the reforming states decline by 7 to 8 percentage points. The coefficient for the female subsample is negative but statistically insignificant in the unrestricted model. However, in the restricted model, the female coefficient

becomes significant and suggests that the mortality rates for females due to suicide increased by 8 percentage points. These results are counterintuitive and suggest that states should investigate qualitative data in their state on individuals seeking mental and behavioral health support to understand what their needs were before expanding prescriptive authority. Overall, suicides may decrease, but some subpopulations may be vulnerable to changes. Table 9 replicates these regressions with the addition of bootstrapped standard errors. In this case we find that there is still a significant increase in female suicide, but this significance is only at the 5% level. Males have a consistent significant reduction in suicide under the bootstrapped methodology.

Tables 10 and 11 present the results for subsample analysis by marital status for both the clustered standard errors and bootstrapped standard errors, respectively. We see no statistically significant effect of the reform on divorced individuals, even though the point estimate is negative in magnitude. Suicide rates for single individuals and married individuals decline by 4 and 6 percentage points. The coefficient for single individuals is only significant at the 10% level. The direction and significance of results is consistent under bootstrapping. To the best of our knowledge, there has not been any study within the literature that looks at the prevalence of individuals with suicidal intentions in attending therapy with a psychologist or psychiatrist. Policymakers in each state should study their state's suicide trends to determine the most atrisk category of people not receiving support. If there is substantial loss of life among married and single individuals, then expanding scope of practice for psychologists to prescribe pharmacological drugs may reduce suicide for these groups. If the concern is divorced individuals, then expanding scope of practice for prescriptive authority does not reduce suicide, but importantly, it also does not increase suicide. In other words, access could be improved without substantial reductions in quality as measured by the worst perceived potential outcome: the loss of life.

Table 12 presents results for different age categories. Table 13 repeats the analysis within the bootstrapped standard error framework. All the coefficients are negative in magnitude, but only significant for age groups 35–44 and 45–54 in the base model. Under bootstrapping we observe significance for ages 15–24, 25–34, 35–45, and 45–54. Reductions in suicide rates are between 4 and 8 percentage points depending on age category, with the largest effects being observed in the 35–44 age range. Within the literature, late 30 and early 40-year-olds make up a disproportionately high percentage of the suicide population, meaning that policy interventions targeting this group can improve outcomes for the most at-risk category.

Finally, Tables 14 and 15 present the race subsample analysis with clustered standard errors and bootstrapped standard errors, respectively. Only the White coefficient is statistically significant at the 5% level within both model frameworks, suggesting a decline in deaths by suicide for White individuals by 5 percentage points relative to White individuals living in nonreforming states. There were no significant reductions in suicide within the Black community. Though there is not a reduction, there is also not a significant increase. If the purpose of this prescriptive authority expansion is to improve access and address concerns about quality of care, a lack of increase is an intuitively interesting result. It means that access can be improved without worsening the most extreme mental and behavioral health outcomes.

We also conduct a variety of additional specifications, the results of which are presented in an online appendix that is available upon request. These additional tests include different forms of smoothing, such as a first order autoregressive model, exponential smoothing, and a random walk, and the results are nearly identical in magnitude and statistical significance.

We conduct the Goodman-Bacon decomposition analysis for the full sample and several subsample analyses. The purpose of the Goodman-Bacon decomposition is to determine if the multiple treatment periods are biasing our difference-in-difference estimates. We present the results in Table 16 for the full sample. The results suggest that for the full sample, results are primarily being driven by the earlier treated groups rather than the later treated groups. The estimated difference-in-difference coefficient for the full sample suggests all three estimates are negative, suggesting that the mortality rate due to suicide is declining between all three treated groups versus the control group. However, the effects are largely being driven by the early treated units compared to the later treated units. We conduct this for all the groups in our analysis in Table 17, and none of the models cause the difference-in-difference estimator to be significantly different after accounting for early and late treatment periods.

6. Conclusion

Limited access to healthcare is linked to poorer health outcomes for many people. This is also true for mental healthcare. Economists and healthcare professionals argue that access to healthcare can be expanded by relaxing scope-of-practice regulations for providers. However, opponents of scope-of-practice expansions argue that the quality of care will be compromised, and the cost of care will increase due to overprescribing or overtesting. Our paper investigates how allowing prescriptive authority to psychologists affects suicide rates, which we argue is the most extreme of mental and behavioral health outcomes and one of the fundamental quality effects involved in prescriptive authority expansions.

Using a restricted mortality data set from the National Center for Health Statistics, we investigate the relationship between suicide and prescriptive authority for psychologists by employing a difference-in-difference estimation technique. In the United States, there can often be weeks or months between the time a psychologist identifies that a patient needs pharmacological intervention and when that patient is able to be seen, assessed, and given treatment by a separate psychiatrist (Malowney et al., 2015). Those weeks or months can be a matter of life or death for individuals with suicidal intentions, but expanding psychologists' prescriptive authority reduces this time delay. Currently, five states have implemented prescriptive authority for psychologists, but it takes a few years for psychologists to fulfill all the requirements to obtain this privilege. Thus we limit our analysis to New Mexico and Louisiana, since they are the only two states to have had enough time for the policy to be integrated.

We find that states that have passed the prescriptive authority laws for psychologists have a 5 to 7 percentage points decrease in their overall suicide rates. These results are diverse within subgroups, with male, married, single, young, and White individuals seeing the largest reduction in suicide rates. We also find some evidence of an increase in female suicide and null results for divorced and Black subgroups. The United States is on the verge of a suicide crisis. Nearly every state has seen substantial increases in suicide rates over the past decade, and policy interventions that address access issues may be one of the most impactful ways to address this growing concern. Policymakers considering expanding the prescriptive authority of psychologists should first analyze trends within the subpopulations, as these expansions may be more impactful for some groups. Regardless, outside of the weakly significant effects for the female population, improving access to pharmacological intervention is not found to worsen the most extreme of quality measures, suicide.

Our results reflect trends that are similar to those observed by Alexander and Schnell (2019), who find that independent prescribing by nurse practitioners reduces suicide-related mortality. It should be noted that there are substantial differences between nurse practitioners and psychologists, and in insurance companies' willingness to cover care. Alexander and Schnell (2019) did not find a reduction in mental health-related mortality when considering all counties, though they did find significant reductions (11%) in counties that are categorized as underserved. We are not able to present results at the county level due to our data usage agreement, but we do find significant reductions in suicide rates between 5 and 7% when considering the entire sample, unlike this previous work. Our results are intuitively similar, but direct comparisons between nurse practitioner and psychologist expansions are not able to be made at this time.

Our analysis is limited to one quality outcome measure, suicide, but it is certainly not reflective of all measure of quality outcomes. We suggest that future research investigate the relationship between these prescriptive authority expansions and a variety of other outcomes, such as depression, anxiety, cost of services, time to diagnosis, time to treatment plan, and the implications for wages for psychologists, psychiatrists, nurse practitioners, physicians, and professionals in other related medical fields.

Our paper suggests that allowing healthcare providers to prescribe controlled substances can improve access to mental and behavioral healthcare services. This is especially important for policymakers to consider now because the United States has been observing a shocking increase in suicide and has also been battling a global pandemic, which is likely to have long-lasting impacts on the population's physical and mental health. Given recent CDC reports that suicide ideation has increased in young adults during COVID-19, we expect to see a rise in the demand for mental health services (Czeisler et al., 2020). Restrictive scope-of-practice regulations reduce access to efficient mental healthcare, which is becoming a more prevalent concern as we emerge from the current pandemic. Our paper suggests that by allowing psychologists to prescribe psychotropic substances, there are reductions in suicide rates and increased access to sufficient treatment.

References

- American Association of Nurse Practitioners. (2016). *AANP national nurse practitioner sample survey*. https://www.aanp.org/advocacy/state/state-practice-environment/state-policy-fact-sheets/new-mexico-state-policy-fact-sheet
- Alexander, D., & Schnell, M. (2019). Just what the nurse practitioner ordered: Independent prescriptive authority and population mental health. *Journal of Health Economics*, 66, 145–162.
- Angrist, J. D., & Pischke, J. (2009). *Mostly harmless econometrics: An empiricists companion*. Princeton University Press.
- Arsenault-Lapierre, G., Kim, C., & Turecki, G. (2004). Psychiatric diagnoses in 3,275 suicides: A meta-analysis. *BMC Psychiatry*, *4*, 37.
- Bachmann, S. (2018). Epidemiology of suicide and the psychiatric perspective. *International Journal of Environmental Research and Public Health*, 15(7), 1425.
- Bishop, T., Press, M., Keyhani, S., & Pincus, H. (2014). Acceptance of insurance by psychiatrists and the implications for access to mental health care. *JAMA Psychiatry*, 71(2), 176–181.
- Brådvik, L. (2018). Suicide risk and mental disorders. *International Journal of Environmental Research and Public Health*, 15(9), 2028.
- Bureau of Health Workforce. (2016). *Designated health professional shortage area statistics*. U.S. Department of Health and Human Services.
- Centers for Disease Control and Prevention. (2018, June). *CDC Vital Signs* [Fact sheet]. https://www.cdc. gov/vitalsigns/pdf/vs-0618-suicide-H.pdf
- Chen, J., Meyerhoefer, C. D., & Timmons, E. J. (2020). *The effects of dental hygienist scope of practice and autonomy on dental care utilization* [Working paper]. Center for Growth and Opportunity at Utah State University. https://www.thecgo.org/research/the-effects-of-dental-hygienist-autono-my-on-dental-care-utilization/
- Chesney, E., Goodwin, G., & Fazel, S. (2014). Risk of all-cause and suicide mortality in mental disorders: A meta-review. *World Psychiatry*, 13(2), 153–160.
- Czeisler, M., Lane, R., Petrosky, E., Wiley, J., Christensen, A., Njai, R., Weaver, M., Robbins, R., Facer-Childs, E., Barger, L., Czeisler, C., Howard, M., & Rajaratnam, S. (2020, August 14). Mental health, substance use, and suicidal ideation during the COVID-19 pandemic — United States, June 24–30, 2020. *Morbidity and Mortality Weekly Report*. Centers for Disease Control and Prevention. https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a1.htm
- Dueker, M., Jacox, A., Kalist, D., & Spurr, S. (2005). The practice boundaries of advanced practice nurses: An economic and legal analysis. *Journal of Regulatory Economics*, 27(3), 309–329.
- Federal Trade Commission. (2014). Competition and the regulation of advanced practice nurses.
- Gibbons, R. D., Hur, K., Bhaumik, K. K., & Mann, J. J. (2005). The relationship between antidepressant medication use and rate of suicide. *JAMA Psychiatry*, 62(2), 165–172.
- Giné, E., & Zinn, J. (1990). Bootstrapping general empirical measures. *The Annals of Probability*, 18(2), 851–869.
- Goodman-Bacon, A. (2018). Difference-in-differences with variation in treatment timing [Working paper]. National Bureau of Economic Research. Doi:10.3386/w25018

- Hartley, D., Hart, V., Hanrahan, N., & Loux, S. (2004). Are advanced practice psychiatric nurses a solution to rural mental health workforce shortage? [Working paper]. Maine Rural Health Research Center.
- Health Resources & Services Administration. (2021, July 18). *Health professional shortage areas (HPSA)*. Retrieved December 19, 2020, from https://data.hrsa.gov/topics/health-workforce/shortage-areas
- Hughes D., Jiang, M., & Duszak, R. Jr. (2015). A comparison of diagnostic imaging ordering patterns between advanced practice clinicians and primary care physicians following office-based evaluation and management visits. *JAMA Internal Medicine*, 175(1), 101–107.
- Kandrack, R., Barnes, H., & Martsolf, G. (2019). Nurse practitioner scope of practice regulations and nurse practitioner supply. *Medical Care Research and Review*.
- Kleiner, M., Marier, A., Park, K., & Wing, C. (2016). Relaxing occupational licensing requirements: Analyzing wages and prices for a medical service. *The Journal of Law and Economics*, 59(2), 261–291.
- Kleiner, M., & Park, K. (2010). Battles among licensed occupations: Analyzing government regulations on labor market outcomes for dentists and hygienists [Working paper]. National Bureau of Economic Research. http://www.nber.org/papers/w165160
- Lang, M. (2013). The impact of mental health insurance laws on state suicide rates. *Health Economics*, 22, 73–88.
- Langelier, M., Continelli, T., Moore, J., Baker, B., & Surdu, S. (2016). Expanded scopes of practice for dental hygienists associated with improved oral health outcomes for adults. *Health Affairs*, 35(12), 2207–2215.
- Malowney, M., Keltz, S., Fischer, D., Boyd, J. (2015). Availability of outpatient care from psychiatrists: a simulated-patient study in three U.S. cities. *Psychiatric Services*, 66(1), 94–96.
- McCarthy, J., Blow, F., Ignacio, R., Ilgen, M., Austin, K., Valenstein, M. (2012). Suicide among patients in the veterans affairs health system: rural-urban differences in rates, risks, and methods. *American Journal of Public Health*, *102*(Suppl 1), S111–S117.
- McMichael, B. (2017). The demand for healthcare regulation: The effect of political spending on occupational licensing laws. *Southern Economic Journal*, *84*(1), 297–316.
- National Center for Health Statistics. (1999–2004). *Multiple cause of death data archive* [Data set]. CDC WONDER, Vital Statistics Cooperative Program. https://wonder.cdc.gov/mcd-v2004.html
- National Center for Health Statistics. (2005–2018). [Vital mortality statistics][Data set]. Vital Statistics Cooperative Program.
- Niederkrotenthaler, T., Logan, J., Karch, D., Crosby, A. (2014). Characteristics of U.S. suicide decedents in 2005-2010 who had received mental health treatment. *Psychiatric Services*, 65(3), 387–390.
- Occupational and Professional Licensing Psychologists and Psychologists Associates Application Procedures: Two-Year Supervised Practice, Title 16 NM, § 22.24 (2009).
- Olfson, M., Shaffer, D., Marcus, S. C., & Greenberg, T. (2003). Relationship between suicide antidepressant medication treatment and suicide in adolescents. *JAMA Psychiatry*, *60*(10) 978–982.
- Phillips, R. Jr., Bazemore, A., & Peterson, L. (2014). Effectiveness over efficiency: Understanding the primary care physician shortage. *Med Care*, *52*(2), 97–98.
- Slivinski, S. (2020). *Members of the occupational licensing board and the barriers to entry* [Research note]. Center for the Study of Economic Liberty. https://csel.asu.edu/research/publications/July-2020-research-note

- Stange, K. (2014). How does provider supply and regulation influence health care markets? Evidence from nurse practitioners and physician assistants. *Journal of Health Economics*, 33, 1–27.
- Stein, J., Kapoor, K., Tootoo, J., Wagner, A., Andrews, C., & Miranda, M. (2017). Access to ophthalmologists in states where optometrists have expanded scope of practice. *JAMA Ophthalmology*, 136(1), 39–45.
- Swan, M., Ferguson, S., Chang, A., Larson, E., & Smaldone, A. (2015). Quality of primary care by advanced practice nurses: A systematic review. *International Journal for Quality in Health Care*, 27(5), 396–404.
- Thomson Healthcare. (2007). Ranking America's mental health: an analysis of depression across the states. Mental Health America.
- Timmons, E. (2017). The effects of expanded nurse practitioner and physician assistant scope of practice on the cost of Medicaid patient care. *Health Policy*, *121*(2), 189–196.
- Timmons, E., & Norris, C. (2018). CLIA waiver pharmacy growth: How does broadening scope of practice affect the pharmacist labor market? [Working paper]. Mercatus Center at George Mason University. doi:10.2139/ssrn.3191398
- Too, L., Spittal, M., Bugeja, L., Reifels, L., Betterworth, P., & Pirkis, J. (2019). The association between mental disorders and suicide: A systematic review and meta-analysis of record linkage studies. *Journal of Affective Disorders*, 259, 302–313.
- Tondo, L., Albert, M., Baldessarini, R. (2006). Suicide rates in relation to health care access in the United States: and ecological study. *Journal of Clinical Psychiatry*, 67(4), 517–523.
- Traczynski, J., & Udalova, V. (2018). Nurse practitioner independence, health care utilization, and health outcomes. *Journal of Health Economics*, 58, 90–109.
- Xue, Y., Ye, Z., Brewer, C., & Spetz, J. (2016). Impact of state nurse practitioner scope-of-practice regulation on health care delivery: Systematic review. *Nurse Outlook*, 64, 71–85.

Appendix

Figure 1







Table 1.

	National Average	LA and NM Treatment States	Treatment States	Nontreatment States
Suicide Rate	14.8 per 100,000	18.6 per 100,000	15.0 per 100,000	14.6 per 100,000
		Sex		
Female	22%	23%	22%	22%
		Marital Status		
Single	39%	41%	41%	38%
Divorced	21%	19%	20%	21%
Married	33%	33%	33%	33%
		Race		
White	89%	83%	89%	89%
Black	7%	9%	7%	7%
		Age		
15 - 24	13%	14%	13%	13%
25 - 34	17%	19%	18%	16%
35 – 44	16%	15%	16%	16%
45 – 54	17%	15%	17%	17%
55 - 64	18%	16%	17%	18%

Summary Statistics for Suicide from the Vital	Mortality Statistics S	Sample in 2018
---	------------------------	----------------

Note. +/- 1.5% for rounding and missing data values. Summary statistics are provided for some select categories. Inclusion or exclusion of variables was determined by the limitations within the data usage agreement for the restricted Vital Mortality Statistics.

Table 2.

	National Average	LA and NM Treatment States	All Treatment States	Nontreatment States
Suicide Rate	10.9 per 100,000	12.5 per 100,000	10.3 per 100,000	11.0 per 100,000
		Sex		
Female	20%	19%	18%	20%
		Marial Status		
Single	32%	36%	34%	32%
Divorced	22%	22%	22%	22%
Married	37%	33%	35%	38%
		Race		
White	90%	87%	91%	90%
Black	6%	7%	6%	6%
		Age		
15 – 24	13%	16%	14%	12%
25 - 34	16%	18%	17%	16%
35 - 44	21%	21%	22%	20%
45 – 54	21%	17%	20%	21%
55 - 64	12%	11%	11%	12%

Summary Statistics for Suicide within the Vital	Mortality Statistics Sample in 2003
---	-------------------------------------

Note. +/- 1.5% for rounding and missing data values. Summary statistics are provided for some select categories. Inclusion or exclusion of variables was determined by the limitations within the data usage agreement for the restricted Vital Mortality Statistics. *Source.* National Center for Health Statistics (1999-2004, 2005–2018).

Table 3.

Parallel Assumption Test for Full Sample

	Loui	isiana	
Variables	Total	Male	Female
Louisiana	1.2229***	1.3068***	0.7286***
	(0.0465)	(0.0528)	(0.0947)
LA * Trend	0.0001	0.0001	0.0005
	(0.0001)	(0.0001)	(0.0001)
Observations	3,666	3,658	3,471
	New	Mexico	
Variables	Total	Male	Female
New Mexico	0.9537***	1.0147***	0.6377***
	(0.0336)	(0.0515)	(0.0676)
NM * Trend	0.0004***	0.0005***	-0.0003***
	(0.0001)	(0.0001)	(0.0001)
Observations	2,442	2,438	2,308

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. Column (1) analyzes the full sample of observations, while Columns (2) and (3) provide a subsample analysis of male and female observations, respectively.

Source. National Center for Health Statistics (1999-2004, 2005-2018).

Table 4.

Parallel Assumption Test by Marital Status

Louisiana						
Variables	Divorced	Married	Single			
Louisiana	1.2823***	1.4602***	1.1950***			
	(0.0691)	(0.0649)	(0.0764)			
LA * Trend	-0.0001	0.0001	0.0002*			
	(0.0001)	(0.0001)	(0.0001)			
Observation	3,479	3,597	3,618			
	New I	Mexico				
Variables	Divorced	Married	Single			
New Mexico	0.9923***	1.0829***	0.9527***			
	(0.0468)	(0.0446)	(0.0518)			
NM * Trend	0.0000	0.0004***	0.0006***			
	(0.0001)	(0.0001)	(0.0001)			
Observations	2,307	2,404	2,409			

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. Column (1) inspects the trend for the divorced subset populations, Column (2) repeats the methodology for the married subpopulation, and Column (3) repeats the analysis for the single subpopulation. *Source*. National Center for Health Statistics (1999-2004, 2005–2018).

Table 5.

Parallel Assumption Test by Race

	Louisiana	
Variables	White	Black
Louisiana	1.1778***	1.0950***
	(0.0730)	(0.1309)
LA * Trend	0.0001	0.0002
	(0.0001)	(0.0002)
Observations	3,643	2,370
	New Mexico	
Variables	White	Black
New Mexico	1.1778***	1.0950***
	(0.0730)	(0.1309)
NM * Trend	0.0001	0.0002
	(0.0001)	(0.0002)
Observations	3,643	2,370

Note. *** p < 0.01, ** p < 0.05, p < 0.10. Column (1) depicts the results of the parallel assumption test for the White subpopulation, while Column (2) depicts the results of the parallel assumption test for the Black subpopulation. *Source*. National Center for Health Statistics (1999-2004, 2005–2018).

Table 6.

Parallel Assumption Test by Age Category

Louisiana					
	Age 15-24	Age 25-34	Age 35-44	Age 45-54	Age 55-64
Louisiana	1.152***	1.2077***	1.1756***	1.2745***	1.2355***
	(0.1225)	(0.0670)	(0.0727)	(0.0618)	(0.0712)
LA * Trend	0.0005***	0.0000	0.0003***	-0.0002	-0.0000
	(0.0001)	(0.0001)	(0.0001)	(0.0001)	(0.0001)
Observation	3,364	3,434	3,501	3,471	3,214
		New	Mexico		
	Age 15-24	Age 25-34	Age 35-44	Age 45-54	Age 55-64
New Mexico	0.8539***	0.9181***	0.8711***	1.3621***	0.9878***
	(0.0982)	(0.0498)	(0.0567)	(0.0268)	(0.0471)
NM * Trend	0.0002	0.0001***	0.0001	-0.0001	-0.0008***
	(0.0001)	(0.0001)	(0.0001)	(0.0001)	(0.0002)
Observations	2,248	2,290	2,333	3,471	2,118

Note. ***p < 0.01, **p < 0.05, *p < 0.10. Columns (1) through (5) depict the results of the parallel assumption test by age group. *Source*. National Center for Health Statistics (1999-2004, 2005–2018).

Table 7.

	All Suicides	All Suicides	All Suicides	All Suicides
Treatment	1.0698***	0.9816***	1.0698***	0.9816***
	(0.0147)	(0.0230)	(0.0216)	(0.0421)
Treatment *	-0.0731***	-0.0483**	-0.0731***	-0.0484**
Post Period	(0.0184)	(0.0214)	(0.0331)	(0.0202)
		State,		State,
	on- State Time	Time,		Time,
		Residency,		Residency,
Additional Con		Education,	State Time	Education,
trols		Marital Status, Age Group,		Marital Status, Age Group,
		Unemployment,		Unemployment,
		Race,		Race,
		Gender		Gender
Standard Er- rors	Cluster(State)	Cluster(State)	Bootstrap	Bootstrap
R ²	0.95	0.96	0.95	0.96
Observations	12,227	12,227	12,227	12,227

Mortality Due to Suicide: Full Sample

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. Columns (1) and (2) use all five treatment states, while Columns (3) and (4) only use LA and NM. The treatment variable is the natural log of mortality resulting from suicide within each individual state, in each individual time period. *Source*. National Center for Health Statistics (1999-2004, 2005–2018).

Table 8.

	Female	Male	Female	Male
Treatment	0.9909***	1.0712***	0.7489***	1.0651***
	(0.0268)	(0.0164)	(0.0620)	(0.0277)
Treatment *	-0.0170	-0.0827***	0.0786**	-0.0687***
Post Period	(0.0332)	(0.0205)	(0.0392)	(0.0232)
			State,	State,
			Time,	Time,
			Residency,	Residency,
Additional	State Time	State Time	Education,	Education,
State-Level Controls			Marital Status, Age Group,	Marital Status, Age Group,
			Unemployment,	Unemployment,
			Race,	Race,
			Gender	Gender
Standard Er- rors	Cluster(State)	Cluster(State)	Cluster(State)	Cluster(State)
R ²	0.85	0.92	0.90	0.93
Observations	12,227	12,227	12,227	12,227

Mortality Due to Suicides: Subsample Analysis by Sex

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. Columns (1) and (3) looks at female mortality due to suicide, while Columns (2) and (4) look at male mortality due to suicide. The treatment variable is the natural log of mortality resulting from suicide within each individual state, in each individual time period.

Table 9.

	Female	Male	Female	Male
Treatment	0.9909***	1.0712***	0.7489***	1.0651***
	(0.0645)	(0.0315)	(0.0541)	(0.0392)
Treatment *	-0.0170	-0.0827***	0.0786**	-0.0687***
Post Period	(0.0475)	(0.0231)	(0.0339)	(0.0233)
			State,	State,
	State S Time T		Time,	Time,
			Residency,	Residency,
Additional		State Time	Education,	Education,
State-Level Controls			Marital Status, Age Group,	Marital Status, Age Group,
			Unemployment,	Unemployment,
			Race,	Race,
			Gender	Gender
Standard Er- rors	Bootstrap	Bootstrap	Bootstrap	Bootstrap
R ²	0.85	0.92	0.90	0.93
Observations	12.227	12,227	12,227	12,227

Mortality Due to Suicides: Subsample Analysis by Sex with Bootstrapped Standard Errors

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. Columns (1) and (3) looks at female mortality due to suicide, while Columns (2) and (4) look at male mortality due to suicide. The treatment variable is the natural log of mortality resulting from suicide within each individual state, in each individual time period.

Table 10.

	Divorced	Married	Single
Treatment	0.9636***	1.0387***	1.0276***
	(0.0307)	(0.0243)	(0.0288)
Treatment *	-0.0326	-0.0608***	-0.0438*
Post Period	(0.0250)	(0.0132)	(0.0458)
	State,	State,	State,
	Time,	Time,	Time,
	Residency,	Residency,	Residency,
Additional	Education,	Education,	Education,
Controls	Marital Status, Age Group,	Marital Status, Age Group,	Marital Status, Age Group,
	Unemployment,	Unemployment,	Unemployment,
	Race,	Race,	Race,
	Gender	Gender	Gender
Standard Error Clustering	Cluster(State)	Cluster(State)	Cluster(State)
R ²	0.94	0.95	0.94
Observations	12,227	12,227	12,227

Mortality Due to Suicides: Subsample Analysis by Marital Status

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. The treatment variable is the natural log of mortality resulting from suicide within each individual state, in each individual time period.

Table 11.

	Divorced	Married	Single
Treatment	0.9636***	1.0387***	1.0276***
	(0.0447)	(0.0378)	(0.0423)
Treatment *	-0.0326	-0.0608***	-0.0438*
Post Period	(0.0250)	(0.0223)	(0.0236)
	State,	State,	State,
	Time,	Time,	Time,
	Residency,	Residency,	Residency,
Additional	Education,	Education,	Education,
Controls	Marital Status, Age Group,	Marital Status, Age Group,	Marital Status, Age Group,
	Unemployment,	Unemployment,	Unemployment,
	Race,	Race,	Race,
	Gender	Gender	Gender
Standard Er- rors	Bootstrap	Bootstrap	Bootstrap
\mathbb{R}^2	0.95	0.95	0.94
Observations	12,227	12,227	12,227

Mortality Due to Suicides: Subsample Analysis by Marital Status with Bootstrapped Standard Errors

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. The treatment variable is the natural log of mortality resulting from suicide within each individual state, in each individual time period.

Table 12.

	15-24	25-34	35-44	45-54	55-64
Treatment	0.9814***	0.9831***	1.0119***	1.007***	0.9233***
	(0.0713)	(0.0297)	(0.0222)	(0.0196)	(0.0404)
Treatment *	-0.0630	-0.0487	-0.0783***	-0.0531***	-0.0025
Post Period	(0.0638)	(0.0297)	(0.1683)	(0.0128)	(0.0205)
	State,	State,	State,	State,	State,
	Time,	Time,	Time,	Time,	Time,
	Residency,	Residency,	Residency,	Residency,	Residency,
Additional	Education,	Education,	Education,	Education,	Education,
Controls	Marital Status, Age Group,				
	Unemployment,	Unemployment,	Unemployment,	Unemployment,	Unemployment,
	Race,	Race,	Race,	Race,	Race,
	Gender	Gender	Gender	Gender	Gender
Standard Error Clustering	Cluster(State)	Cluster(State)	Cluster(State)	Cluster(State)	Cluster(State)
R ²	0.90	0.92	0.93	0.94	0.93
Observations	12,227	12,227	12,227	12,227	12,227

Mortality Due to Suicides: Subsample Analysis by Age Group

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. The treatment variable is the natural log of mortality resulting from suicide within each individual state, in each individual time period.

Table 13.

	15-24	25-34	35-44	45-54	55-64
Treatment	0.9814***	0.9831***	1.0119***	1.007***	0.9233***
	(0.0436)	(0.0446)	(0.0395)	(0.0433)	(0.0489)
Treatment *	-0.0630**	-0.0487*	-0.0783***	-0.0531*	-0.0025
Post Period	(0.0269)	(0.0280)	(0.0248)	(0.0283)	(0.0342)
	State,	State,	State,	State,	State,
	Time,	Time,	Time,	Time,	Time,
	Residency,	Residency,	Residency,	Residency,	Residency,
Additional	Education,	Education,	Education,	Education,	Education,
Controls	Marital Status, Age Group,				
	Unemployment,	Unemployment,	Unemployment,	Unemployment,	Unemployment,
	Race,	Race,	Race,	Race,	Race,
	Gender	Gender	Gender	Gender	Gender
Standard Er- rors	Bootstrap	Bootstrap	Bootstrap	Bootstrap	Bootstrap
\mathbb{R}^2	0.90	0.92	0.93	0.94	0.93
Observations	12,227	12,227	12,227	12,227	12,227

Mortality Due to Suicides: Subsample Analysis by Age Group with Bootstrapped Standard Errors

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. The treatment variable is the natural log of mortality resulting from suicide within each individual state, in each individual time period.

Table 14.

	White	Black	
Treatment	0.9896***	0.2730*	
	(0.0309)	(0.1559)	
Treatment *	-0.0505**	-0.0014	
Post Period	(0.0220)	(0.0132)	
	State,	State,	
	Time,	Time,	
	Residency,	Residency,	
A d d:4: or ol	Education,	Education,	
Controls	Marital Status, Age Group,	Marital Status, Age Group,	
	Unemployment,	Unemployment,	
	Race,	Race,	
	Gender	Gender	
Standard Error Clustering	Cluster(State)	Cluster(State)	
R ²	0.96	0.83	
Observations	12.227	12.227	

Mortality Due to Suicides: Subsample Analysis by Race

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. The treatment variable is the natural log of mortality resulting from suicide within each individual state, in each individual time period.

Table 15.

	White	Black	
Treatment	0.9896***	0.2730***	
	(0.0428)	(0.0681)	
Treatment *	-0.0505**	-0.0014	
Post Period	(0.0200)	(0.0353)	
	State,	State,	
	Time,	Time,	
	Residency,	Residency,	
A d d:::: = = = 1	Education,	Education,	
Controls	Marital Status, Age Group,	Marital Status, Age Group,	
	Unemployment,	Unemployment,	
	Race,	Race,	
	Gender	Gender	
Standard Error Clustering	Bootstrap Bootstra		
R ²	0.96	0.83	
Observations	12.227	12.227	

Mortality Due to Suicides: Subsample Analysis by Race with Bootstrapped Standard Errors

Note. *** p < 0.01, ** p < 0.05, * p < 0.10. The treatment variable is the natural log of mortality resulting from suicide within each individual state, in each individual time period.

Source. National Center for Health Statistics (1999-2004, 2005-2018).

Table 16.

Goodman-Bacon Decomposition for the Full Sample

Full Sample	;	
Difference-in-Difference Estimate	-0.068	
	Weight	Avg DD Est
Earlier Treated vs. Later Control	0.188	-0.042
Later Treated vs. Earlier Control	0.004	-0.052
Treated vs. Never Treated	0.808	-0.075

Note. Early T refers to early treatment states (New Mexico). Late T refers to Louisiana. Never treated refers to states that did not reform their scope-of-practice law allowing psychologists to prescribe controlled substances. The weights suggest which group contributes to the DD estimate. *Source.* National Center for Health Statistics (1999-2004, 2005–2018).

Table 17.

Male	Subsample		Female Subsample		Divorced Subpopulation			
DD Est	-0.076		DD Est	0.140		DD Est	-0.018	
	Weight	Avg DD Est		Weight	Avg DD Est		Weight	Avg DD Est
Earlier Treated vs. Later Control	0.182	-0.030	Earlier Treated vs. Later Control	0.325	-0.464	Earlier Treated vs. Later Control	0.326	0.020
Later Treated vs. Earlier Control	0.004	-0.035	Later Treated vs. Earlier Control	0.007	-0.358	Later Treated vs. Earlier Control	0.007	-0.035
Treated vs. Never Treated	0.814	-0.086	Treated vs. Never Treated	0.668	-0.020	Treated vs. Never Treated	0.667	-0.036
Married Subpopulation		Single Subpopulation			Age 15-24 Subpopulation			
DD Est	-0.018		DD Est	-0.081		DD Est	-0.140	
	Weight	Avg DD Est		Weight	Avg DD Est		Weight	Avg DD Est
Earlier Treated vs. Later Control	0.326	0.020	Earlier Treated vs. Later Control	0.170	-0.116	Earlier Treated vs. Later Control	0.188	-0.251
Later Treated vs. Earlier Control	0.007	-0.035	Later Treated vs. Earlier Control	0.004	-0.117	Later Treated vs. Earlier Control	0.004	-0.241
Treated vs. Never Treated	0.667	-0.036	Treated vs. Never Treated	0.827	-0.073	Treated vs. Never Treated	0.808	-0.113
Age 25-34	Subpopula	ation	Age 35-44 Subpopulation		Age 45-54 Subpopulation			
			0			0	1 1	
DD Est	-0.023		DD Est	-0.120		DD Est	-0.096	
DD Est	-0.023 Weight	Avg DD Est	DD Est	-0.120 Weight	Avg DD Est	DD Est	-0.096 Weight	Avg DD Est
DD Est Earlier Treated vs. Later Control	-0.023 Weight 0.188	Avg DD Est 0.076	DD Est Earlier Treated vs. Later Control	-0.120 Weight 0.188	Avg DD Est -0.125	DD Est Earlier Treated vs. Later Control	-0.096 Weight 0.188	Avg DD Est -0.021
DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control	-0.023 Weight 0.188 0.004	Avg DD Est 0.076 0.067	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control	-0.120 Weight 0.188 0.004	Avg DD Est -0.125 -0.125	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control	-0.096 Weight 0.188 0.004	Avg DD Est -0.021 -0.051
DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated	-0.023 Weight 0.188 0.004 0.808	Avg DD Est 0.076 0.067 0.010	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated	-0.120 Weight 0.188 0.004 0.808	Avg DD Est -0.125 -0.125 -0.118	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated	-0.096 Weight 0.188 0.004 0.808	Avg DD Est -0.021 -0.051 -0.114
DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Age 55-64	-0.023 Weight 0.188 0.004 0.808 Subpopula	Avg DD Est 0.076 0.067 0.010	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated White Su	-0.120 Weight 0.188 0.004 0.808	Avg DD Est -0.125 -0.125 -0.118	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Black S	-0.096 Weight 0.188 0.004 0.808 Subpopulatic	Avg DD Est -0.021 -0.051 -0.114
DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Age 55-64 DD Est	-0.023 Weight 0.188 0.004 0.808 Subpopula 0.031	Avg DD Est 0.076 0.067 0.010	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated White St DD Est	-0.120 Weight 0.188 0.004 0.808 ubpopulati -0.066	Avg DD Est -0.125 -0.125 -0.118	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Black S DD Est	-0.096 Weight 0.188 0.004 0.808 Subpopulatic -0.003	Avg DD Est -0.021 -0.051 -0.114
DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Age 55-64 DD Est	-0.023 Weight 0.188 0.004 0.808 Subpopula 0.031 Weight	Avg DD Est 0.076 0.067 0.010 ation Avg DD Est	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated White St DD Est	-0.120 Weight 0.188 0.004 0.808 1bpopulati -0.066 Weight	Avg DD Est -0.125 -0.125 -0.118 ion Avg DD Est	DD Est DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Black S DD Est	-0.096 Weight 0.188 0.004 0.808 <u>Subpopulatic</u> -0.003 Weight	Avg DD Est -0.021 -0.051 -0.114 on Avg DD Est
DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Age 55-64 DD Est Earlier Treated vs. Later Control	-0.023 Weight 0.188 0.004 0.808 Subpopula 0.031 Weight 0.188	Avg DD Est 0.076 0.067 0.010 ation Avg DD Est 0.144	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated White St DD Est Earlier Treated vs. Later Control	-0.120 Weight 0.188 0.004 0.808 ibpopulati -0.066 Weight 0.188	Avg DD Est -0.125 -0.125 -0.118 ion Avg DD Est -0.044	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Black S DD Est Earlier Treated vs. Later Control	-0.096 Weight 0.188 0.004 0.808 <u>Subpopulatic</u> -0.003 Weight 0.188	Avg DD Est -0.021 -0.051 -0.114 on Avg DD Est 0.111
DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Age 55-64 DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control	-0.023 Weight 0.188 0.004 0.808 <u>Subpopula</u> 0.031 Weight 0.188 0.004	Avg DD Est 0.076 0.067 0.010 ation Avg DD Est 0.144 0.134	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated White Su DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control	-0.120 Weight 0.188 0.004 0.808 1bpopulati -0.066 Weight 0.188 0.004	Avg DD Est -0.125 -0.125 -0.118 ion Avg DD Est -0.044 -0.055	DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control Treated vs. Never Treated Black S DD Est Earlier Treated vs. Later Control Later Treated vs. Earlier Control	-0.096 Weight 0.188 0.004 0.808 <u>Subpopulatic</u> -0.003 Weight 0.188 0.004	Avg DD Est -0.021 -0.051 -0.114 on Avg DD Est 0.111 0.129

Goodman-Bacon Decomposition for All Subsamples

Note. Early T refers to early treatment states (New Mexico). Late T refers to Louisiana. Never treated refers to states that did not reform their scope-of-practice law allowing psychologists to prescribe controlled substances. The weights suggest which group contributes to the DD estimate. *Source.* National Center for Health Statistics (1999-2004, 2005–2018).